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tudes in clinical practice. Data was collected on 1648 patients with T2DM receiving
at least one oral anti-diabetic with/without insulin and 141 specialists and 59 in-
ternal medicine physicians in 9 Chinese cities, through physician interviews, pa-
tient record forms, and self-completed questionnaires. RESULTS: Among the 200
physicians in the study, the most frequently reported concerns with starting insu-
lin were patient’s acceptance and ability to comply in the long-term (91.9% of
respondents), and the long timeneeded to train on injection techniques and dosing
(74.0%). Forty-three percent of physicians believe patients fear injections, but a
higher percentage of patients (55.3%) report not liking injections. Thirty-seven per-
cent of physicians believe social stigma is a barrier; only about 17.1% of insulin-
naive patients believe so. Among 474 insulin-naive patients, the most frequently
reported concern was that starting insulin would mean their diabetes is at an
advanced stage (67.5% of respondents). Physicians underestimate that concern,
with only 30% reporting that as a barrier. Almost half of insulin-naive patients
(45.1%) would consider insulin initiation as a personal failure to control their dia-
betes. Among 346 patients taking insulin, 60.1% reported feeling better and 55.7%
felt amore positive outlook since starting insulin; 59.8% thought insulinmade their
diabetes easier tomanage. CONCLUSIONS: Physicians in Chinamay over or under-
estimate patient perceived barriers to, and satisfaction with, insulin initiation.
Physician/patient education focused on perceived barriers to insulin initiation, and
patient/physician communication may facilitate the initiation of insulin in pa-
tientswith this progressive disease. Interventions to address system-level barriers,
e.g. time for training, are warranted.
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OBJECTIVES: To examine the effects on the health-related quality of life (HRQoL)
after starting insulin with, or switching to, biphasic insulin aspart 30 (BIAsp30) in
Chinese subjects with type 2 diabetes (T2DM) in the A1chieve study. METHODS:
The A1chieve study was a 24-week, prospective, non-interventional, observational
study conducted in routine clinical practices in 28 countries. In China, there were
8,578 T2DMpatients recruited from 131 hospitals into the BIAsp30 treatment group
(starting insulin with or switching to BIAsp30 at baseline based on physicians’
clinical judgments). HRQoLwas assessed at baseline and 24weeks by the validated
EQ-5D questionnaire (five dimensions and visual analogue scale (VAS)). Descriptive
statistics, paired t-test, and chi-square were conducted for the analyses. RESULTS:
Themean age of patients (SD) was 54.914.4 years. 57% were male. The reported
HRQoL as measured by VAS score (on a scale of 0-100) increased by 6.2 from 75.8 to
82.0 for the overall cohort (p0.001). For insulin naïve patients, starting insulin
with BIAsp30 was associated with a 6.1 increase in VAS score from 75.9 to 82.0
(p0.001). Similarly, for insulin experienced patients, switching to BIAsp30 was
associated with a 6.7 increase in VAS score from 75.3 to 82.0 (p0.001). For the
overall cohort in the five dimensions of EQ-5D, the percentage of patients reported
no problems in walking increased from 88.4% to 91.4% (p0.0001) after 24 weeks.
Similarly, the percentage of patients reported no pain or discomfort increased from
77.3% to 82.8% (p0.0001), reported not anxious or depressed increased from 74.2%
to 77.1% (p0.001). The percentage of patients reported no problems in self-care
and usual activity only slightly reduced (-0.2%, -0.5%, respectively) with no statis-
tical significance. CONCLUSIONS: Starting insulin with, or switching to, BIAsp30
were associated with significant HRQoL improvement in Chinese T2DM subjects of
the A1chieve study.
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Psychological distress often occurs in patients with diabetes, resulting in poorer
therapeutic outcomes. The Problem Areas in Diabetes (PAID) questionnaire covers
frequently reported diabetes related emotional problems. Utilizing PAID to identify
distressed diabetic patients would be beneficial. OBJECTIVES: PAID was originally
developed for the American population. Cross-cultural differences in health per-
ceptions are well documented; thus it is necessary to verify the validity and reli-
ability of PAID in Singapore. Design: Cross-sectional study. PARTICIPANTS: Pa-
tients with Type 2 diabetes, 21-65 years old, English-speaking, without obvious
cognitive impairment and visited the Diabetes Clinic at National University
Hospital.METHODS: Validity of the scale was evaluated by factor analysis, known
group (defined by socio-demographics and clinical variables), convergent/diver-
gent and concurrent validity. Reliability (internal consistency) was evaluated by
Cronbach’s alpha. RESULTS: Exploratory factor analysis revealed three factors. All
items loaded onto one factor (distress related problems). A few items loaded onto
multiple factors. PAID scores were significantly higher in patients with HbA1c 7.5%
(p0.02) and living in HDB 5-room or smaller flats (p0.01), supporting known
group validity. Other hypothesized known group differences were not observed.
PAID correlated significantly with Kessler10 (K10) and World Health Organization
Quality of Life (WHOQOL-BREF), thus demonstrating convergent and concurrent
validity. PAID correlatedweaklywithWHOQOL-BREF’s physical domain, thus dem-
onstrating divergent validity. Internal consistency was high (Cronbach’s
alpha0.96). CONCLUSIONS: PAID is a valid and reliable scale to evaluate diabetes-
related emotional distress in the Singaporean Type 2 diabetes population. Further
evidence on known group validity needs to be accumulated in future studies.
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OBJECTIVES: To examine the association between glycemic control and quality of
life (QoL) among patientswith type 2 diabetesmellitus (T2DM) in China.METHODS:
Data were obtained from a cross-sectional survey of T2DM patients in outpatient
settings from October to December 2011 in Beijing and Tianjin. Eligible patients
were 18 years, had a diagnosis of T2DM 1 year and received 1 year anti-
diabetic treatment at the time of survey. EQ-5D index score and visual analog scale
(VAS) score were calculated for all T2DM patients and compared between sub-
groups defined by fasting blood glucose control (FBG8 mmol/L) and 2-hour post-
prandial glucose control (2h-BG10mmol/L).Multivariate linear regressionmodels
were applied to assess the associations between glucose control and patient QoL,
adjusting for age, gender, BMI, weight gain, education and life style (including
smoking, drinking and exercise). RESULTS: A total of 500 patients with T2DMwere
included in the analysis with 54.6% female, mean age of 63.2 years and mean
disease duration of 11.5 years. Among them, 64.6% reported FBG8mmol/L and
45.6% reported 2h-BG10mmol/L based on the last test in the past 2 weeks. Mean
EQ-5D and VAS scores for all patients were 0.78 and 68.25, respectively. Compared
with patients without FBG control, patients with FBG control had significantly
higher EQ-5D (0.80 vs. 0.75, P0.005) and VAS scores (69.40 vs. 66.16, P0.017).
Similarly, patients with 2h-BG control had significantly higher scores than those
without 2h-BG control (0.82 vs. 0.75 for EQ-5D; 71.82 vs. 65.26 for VAS, both
P0.001). The regression analysis showed that 2h-BG control, but not FBG control,
was significantly associatedwith higher EQ-5D (P0.035) and VAS scores (P0.000).
Older age, less education, weight gain and less exercise were also significantly
associated with lower QoL. CONCLUSIONS: Better glycemic control at 2-hour post-
prandial is associated with improved QoL in patients with T2DM.
INFECTION - Clinical Outcomes Studies
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OBJECTIVES: To assess efficacy and safety of tenofovir (TDF) as compared with
other nucleot(s)ide analogues (NAs) and peginterferon alpha 2a (PegIFN2a) for
naive chronic hepatitis B.METHODS: Comparison was based on randomized con-
trolled trials (RCTs) identified bymeans of systematic review, carried out according
to the Cochrane Collaboration guidelines. Studies met the inclusion criteria if they
directly compared at least two of the following interventions: TDF, PegIFN2a ETV,
ADV, LAMor placebo. Themost importantmedical databases (MEDLINE, CENTRAL,
EMBASE) were searched until February 2012. Two reviewers independently se-
lected trials, assessed their quality and extracted data. Mixed treatment compari-
son (MTC) was performed using WinBugs software. Subgroup analysis was per-
formed according hepatitis B antigen e status. RESULTS:We identified 20 relevant
studies. The results of MTC showed that in app. one year of follow up TDF signifi-
cantly increased the odds of HBV DNA clearance when compared with PegIFN2a
(OR 66.22 [5.98; 733.54]); ETV (OR 8.45 [1.12; 63.98]); ADV (OR 13.04 [3.62; 46.94])
and LAM (OR 41.72 [5.27; 330.54]). TDF was superior than PegIFN2a with respect
to ALT normalization (OR  3.07 [1.04; 9.09]) but did not differ significantly from
other NAs. Percentage of patients with any adverse events was significantly lower
in TDF group when compared with PegIFN2a (OR  0.19 [0.07; 0.48]), while no
differenceswere found between TDF and placebo aswell as other NAswith respect
to the safety profile. The rates of ALT flares were similar in all treatments arms. In
contrast to other NAs there were no resistance to TDF through five years.
CONCLUSIONS: TDF demonstrated the highest efficacy with respect to the reduc-
tion of viral load in treatment naïve patients with chronic HBV and maintained a
very good safety profile.
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OBJECTIVES: To evaluate the relative diagnostic performance of genotypic se-
quencing and enhanced-sensitivity phenotypic testing methods for: i) identifying
the tropism of HIV-1 infected patients, and ii) predicting virological response to
CCR5-antagonist therapy. METHODS: A systematic review of the literature (via
EMBASE and Medline databases) initially identified 359 publications. Based on a
priori defined eligibility criteria, five studies were included in the final analysis.
RESULTS: Four of the five studies assessed the diagnostic performance of genotypic
testing in identifying viral tropism, with the enhanced-sensitivity Trofile assay
(ESTA) as the reference standard. Using the geno2pheno bioinformatic algorithm,
genotypic testing maintained a high concordance with ESTA (range: 70.6%-85.3%).
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At a false-positive rate (FPR) of 5%, specificity for R5-tropic virus was also high
(range: 85.7%-95.3%), but came at the expense of sensitivity for X4-using virus
(range: 36.7%-66.7%). One study compared the effectiveness of both genotypic tro-
pism testing and ESTA in predicting virological response to the CCR5-antagonist
maraviroc. The study found in each screening group, a similar proportion of pa-
tients achieved a viral load 50 HIV-1 RNA copies/mL byWeek 48. CONCLUSIONS:
In the absence of a ‘gold standard’, clinical response to CCR5-anatagonist therapy offers
the bestmeasure of diagnostic performance in HIV-1 tropism testing. The results of this
review indicate that genotypic sequencing of the V3 loop is as capable of predicting re-
sponse toCCR5-antagonist therapyas the currentdiagnostic standard, ESTA. Inaddition,
of the bioinformatic algorithms reviewed here, the geno2pheno model set at 5-10% FPR
offered the best balance between sensitivity and specificity. This evidence provides fur-
ther support for the use of genotypic tropism testing in routine clinical practice.
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OBJECTIVES: To evaluate the relationship between vancomycin trough concentra-
tion and the clinical outcome in hospitalized patients with ORSA bacteremia, and
to assess the relationship between vancomycin trough concentration and
nephrotoxicity. METHODS: Adult patients admitted to National Cheng-Kung Uni-
versity Hospital during January 20, 2006 and July 31, 2006 and treated with vanco-
mycin for ORSA bacteremia were eligible for this prospective observational study.
On the fourth day after vancomycin use, vancomycin concentration was moni-
tored and blood culture was repeated. Regular biochemistry and blood test on day
4, 7, 11, 14, daily highest temperatue and other associated data were collected. The
primary endpoints are the clinical outcome and the change of serum creatinine
concentration. RESULTS: Nineteen patients were enrolled during this period. On
day 4, trough concentration of vancomycin was associated with the rate of defer-
vescence. The afebrile rate were 85.7% and 33.3% among patients with trough level
of above and below 15 g/mL, respectively (P  0.05). For the ratio of vancomycin
trough concentration to MIC, patients with ratio greater than 10 had a trend of a
higher defervescence rate in comparison with those with ratio less than 10 (77.8%
vs. 30%, P  0.07). In addition, nephrotoxicity was found in five patients, but the
mean trough concentrations were not significantly different between the nephro-
toxic and non-nephrotoxic groups. CONCLUSIONS: The result of the study shows
that higher serum vancomycin trough concentration is associated with the defer-
vescence rate on day 4 when vancomycin is used to treat ORSA bacteremia. Be-
sides, under the condition of regular therapeutic drug monitoring, the nephrotox-
icity during vancomycin therapy doesn’t seem to be associated with trough
concentration, but it needs studies with large sample size to evaluate.
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OBJECTIVES: Large antimicrobial consumption in intensive care units (ICUs) con-
tributes heavy health care burden in Taiwan. This study evaluates the short term
influence of pharmacist-led antimicrobial stewardship (PLAS) in ICUs.METHODS:
A prospective PLAS program was implemented in medical and surgical ICUs, in-
cluding dose optimization (renal dose monitoring and therapeutic drug monitor-
ing), streamlining or de-escalation of therapy, antimicrobial order forms, and an-
timicrobial treatment duration review, which any antimicrobial duration over
7days was reviewed. Data collection was from October 19, 2011 to December 2,
2011. Patients who admitted to ICU and received at least one parenteral antimicro-
bial were included. Outcomes included suggestion implementation rate of phar-
macist interventions and cost that saving from dose optimization. Feedbacks of
non-accepted suggestions were also addressed. RESULTS: Sixty-two (21%) of study
population received 88 suggestions. Sixty-two (70.5%) suggestions were imple-
mented. Themajority of suggestions is duration review (30.7%) followed by stream-
lining or de-escalation of therapy (30.6%) and dose optimization (27.3%). There was
76,238 NTDs saving from renal dose monitoring. Further efforts we can make are
found from reasons of non-accepted suggestion. For example, education on pro-
phylactic antibiotics and antimicrobial renal dosage adjustment should be
provided. Since, we found that prolonged (3days) post-operation antimicrobial
prophylaxis until inserted drainage lumen removed and refusing dose increasing
because impaired renal function was expected by doctors. Involvement in multi-
disciplinary specialists is required due to denials from no recommendation from
infectious disease physicians. CONCLUSIONS: A PLAS efforts rationale antimicro-
bial utilization and leads to potential reduction in both the incidence of adverse
effects and the burden of health care. Through feedback from refused suggestion,
however, we found that antimicrobial stewardship should include a multidisci-
plinary team, especially incorporating with infectious disease physicians.
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OBJECTIVES: The optimal timing of initiation of Antiretroviral Therapy (ART) in
ART naïve patients with HIV and TB co-infection remains inconclusive. IRIS inci-
dence is one of the most important outcomes that we need to consider when
making a decision on the time of initiating ART. This study compared the IRIS
incidence in patients initiating ART earlier (2 months after the start of tubercu-
losis therapy) versus later (2 months after the start of tuberculosis therapy). We
also examined the differences of IRIS incidence between early and late arms in the
Resources limited settings (RLS) and the Non Resources limited settings (NRLS).
METHODS:Data for this meta-analysis were extracted from Pubmed/Medline, Em-
base, Cochrane database of systematic review, Cochrane Central Register of Con-
trolled Trials, International Pharmaceutical Abstracts, ClinicalTrials.gov and
Google Scholar from year 1986 to 2011. We searched by using a combination of
terms: HIV, HIV infections, acquired immunodeficiency syndrome, tuberculosis,
TB, HAART, highly active antiretroviral therapy, ART, antiretroviral therapy. Out of
the 11300 studies found in the search, five cohort studiesmet the inclusion criteria.
Among the five studies, two were located in RLS and three were located in NRLS.
We conducted a meta-analysis of these five studies by using STATA SE version 12.
RESULTS:Meta-analysis results showed that overall, people treated with ART ear-
lier during TB therapy had a 12.9% lower risk of IRIS incidence compared to people
treated later (RR, 0.871; 95% CI, 0.831-0.912). In addition, the differences of IRIS
incidence between early and late arms were significant in both the Resources lim-
ited settings (RLS) and the Non Resources limited settings (NRLS). CONCLUSIONS:
Initiating antiretroviral therapy less than 2 months after the start of tuberculosis
therapy is associated with a significantly lower risk of IRIS incidence, regardless of
the locations.
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OBJECTIVES: To report clinical burden of Japanese encephalitis (JE) in Asia and
cost-effectiveness of JE vaccination program. METHODS: Systematic literature
searches were conducted using Embase®, MEDLINE®, WHO, and Google scholar
platforms to identify relevant studies in patients with JE. Eligibility of trials was
assessed by two reviewerswith any discrepancy reconciled by a third, independent
reviewer. RESULTS: A total of 10 studies out of 41 retrieved, met the inclusion
criteria for the clinical review. Approximately 35,000-50,000 JE cases and 10,000–
15,000 deaths due to JE were reported every year in Asia. Incidence of JE was high in
China and India, with China accounting for 50% of the JE cases reportedworldwide.
The incidence of JE in China was reported to be 0.01-1.53 residents/year/100,000.
The number of JE cases reported in China, India, Nepal, Sri Lanka, and Bangladesh
were 5,000-10,000, 1,500-4,000, 1,000-3,000, 100-200, and 56, respectively. JE caused
12,038 and 2,496 deaths in Southeast Asia andWestern Pacific, respectively (2008).
JE was associated with 491,797 disability-adjusted life years (DALYs) in the South-
east Asia and 185,573 DALYs in the Western Pacific region (2004). Four studies out
of 59 retrieved, met the eligibility criteria for evaluating cost-effectiveness of JE
vaccination. JE vaccination prevented 117 cases and 12 deaths (Vietnam), 103 cases
and 18 deaths (Thailand), 420 cases and 105 deaths (China), and 175-316 cases and
36-65 deaths (India). Total savings in the direct medical costs witnessed as a con-
sequence of JE vaccination were $51,122 (Vietnam), $58,776 (Thailand), $614,762
(China), and $178,558-$319,627 (India). CONCLUSIONS: JE has lead to significant
morbidity in survivors and mortality in Asian countries. Existing evidence from
cost-effectiveness studies demonstrated that vaccination program markedly re-
duced the burden of JE in Asia.
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Pathak P, Rana C
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OBJECTIVES: To assess the incidence and distribution of infectious diseases which
have been markedly affected by climate change. METHODS: Literature searches
were performed using Embase®, MEDLINE®, Google Scholar, and WHO website.
RESULTS: Current evidence suggests that inter-annual and inter-decadal climate
variability have a direct impact on the epidemiology of infectious diseases. Accord-
ing to WHO, since mid-1970s, climatic changes have caused annually over 150 000
deaths and an approximately 5 million disability-adjusted life-years, mainly in
developing countries. Malaria has been considered as an extremely climate-sensi-
tive disease. A temperature rise of 2°C-3°C increases the risk of malaria by 3%-5%.
Across the world, the incidence cases of malaria increased from 233 000 in 2000 to
244 000 in 2005, with highest incidence observed in Africa. The West Nile virus
(WNV) disease is considered as an emerging epidemic in the US. More than 7000
neuroinvasiveWNV disease cases were reported in the US from 1999-2004. Parallel
to rising temperatures, the US has recorded a 41% increase in vibrio infection rate
from 1996-2006. In continental Europe, a temperature rise of 6°C above the mean
resulted in an estimated 30% reported cases of salmonellosis. In Russia, rising
temperatures from 2001 have increased the incidence of tick-borne encephalitis
(TBE) by 10-fold within a decade. Korea’s climatic variability has also been posi-
tively correlatedwith the incidence cases ofmalaria, Vibrio vulnificus sepsis, scrub
typhus, leptospirosis, and Hantavirus infection during 2001-2008. Further, in 2009-
2010, government officials of Europe have predicted that borreliosis, WNV fever,
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